THE MOG BLOG

For many people living with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), one of the biggest unanswered questions comes after recovery from an attack: Will it happen again?

While some people experience only a single episode, others develop a relapsing form of the disease. Because every relapse can affect vision, mobility, or other neurological functions, researchers around the world are working to better understand who is most at risk.

One promising area of research focuses on biomarkers — measurable biological signs that may help predict whether a patient is likely to relapse. Recent studies suggest that people whose blood continues to test positive for MOG antibodies over time may have a greater chance of experiencing future attacks. Researchers have also found that patients whose antibody levels eventually become negative appear to have a lower risk of relapse, although this is not a guarantee.

Scientists are also developing tools that combine multiple factors, including age, clinical symptoms, MRI findings, and laboratory results, to estimate an individual’s relapse risk. While these prediction models are still being tested and are not yet accurate enough for routine clinical use, they represent an important step toward more personalized care.

Researchers emphasize that MOGAD remains highly unpredictable. A recent international study found that no single test can reliably determine whether someone will relapse, highlighting the need for larger studies and better biomarkers before these tools can guide treatment decisions.

Although predicting relapses remains a challenge today, progress is being made. As researchers gather more long-term data from patients worldwide, physicians may one day be able to identify higher-risk individuals earlier, personalize follow-up care, and make more informed decisions about preventive treatments.

For the MOGAD community, that future could mean fewer surprises — and more confidence in what comes next.

For many MOGAD patients, the road to diagnosis is long, painful, and filled with uncertainty. However, with artificial intelligence on the horizon, that might just change.

Researchers at Emory University are among those leading this difference. Their team is actively using AI to analyze patient samples to detect biomarkers that can possibly, in the future, make it so that diagnosing MOGAD is easier and less difficult, even making it possible to predict relapses in patients.

One of the most promising areas involves MRI imaging. Scientists are investigating whether a pattern called leptomeningeal enhancement (LME), which is detectable on a standard MRI, and could serve as a biomarker for MOGAD, potentially identifying the disease within days, while antibody test results labs can take some time for them to return.

In the end, artificial intelligence is rapidly transforming medical diagnostics, pushing the drive for more efficient clinical decision-making, with the systems being pointed towards diseases like MOGAD, helping families and patients through their journey.